Single-Agent Therapy for Hodgkin's Disease

Carter, Stephen K.

doi:10.1001/archinte.1973.00320090067007

Cited by 32 publications

(2 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of course it was our concern that an already occult malignancy had been further masked by partial treatment. However, it is unlikely that these drugs singly or together in the doses used were adequate to induce remission of Hodgkin's disease (9,10).…”

Section: Discussionmentioning

confidence: 99%

Hodgkin's Disease Presenting with Fulminant Liver Disease

Gunasekaran,

Hassall,

Dimmick

et al. 1992

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Hodgkin's Disease Presenting with Fulminant Liver Disease

Gunasekaran,

Hassall,

Dimmick

et al. 1992

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

“…Vinblastine, a vinca alkaloid, is a highly effective agent for patients with HD. Early studies have shown a response rate of 90% and a cure rate of 10% when it is used as singleagent front-line therapy [54]. It has also been studied in the relapsed setting at the National Cancer Institute in 17 patients who experienced treatment failure with autologous transplantation [55].…”

Section: Single-agent Therapymentioning

confidence: 99%

Salvage Therapy in Hodgkin's Lymphoma

Byrne

Gockerman

2007

The Oncologist

View full text Add to dashboard Cite

Hodgkin's disease is a rare malignancy that affects approximately 7,500 patients per year in the U.S., leading to an estimated 1,400 deaths. The relapse rate for this disease varies from around 5% for early-stage disease to 35% for patients with advanced disease. Patients who relapse after chemotherapy have about a 20% cure rate with conventional salvage chemotherapy. Two randomized phase III studies have shown an improved failure-free survival rate with high-dose chemotherapy and autologous stem cell support compared with conventional chemotherapy in re- CASE PRESENTATIONMr. T is a 50-year-old African-American male with a past medical history significant for type 2 diabetes mellitus. In January 2002, he presented to the emergency room with complaints of fever, chills, right groin pain, and a 25-pound weight loss over the last several months. Initial laboratory evaluation revealed an elevated white cell count of 11,800, hemoglobin of 11.7 g/dl, hematocrit of 35.8, platelet count of 406,000, and an elevated blood sugar of 516 mg/dl. A chest radiograph revealed right paratracheal lymphadenopathy and a patchy density overlying the left upper lung field. A computed tomography (CT) scan of the chest, abdomen, and pelvis showed enlarged lymph nodes in the mediastinum and the prevascular, right paratracheal, subcarinal, left axillary, left subclavian, azygoesophageal recess, and inguinal and bilateral iliac regions. A biopsy of the enlarged right cervical lymph node revealed fibrofatty connective tissue. A mediastinoscopy with biopsy was performed, and the pathology revealed mixed cellularity-type Hodgkin's lymphoma (Fig. 1). A gallium scan was positive in the mediastinal, left axillary, and right inguinal nodes. A bone marrow biopsy revealed Hodgkin's lymphoma, and the patient was considered to have clinical-stage IVB disease (Fig. 2). He underwent treatment with adriamycin, bleomycin, vincristine, and dacarbazine (ABVD) chemotherapy for four cycles. Restaging gallium scan was negative for nodal uptake, and a CT scan showed significant decrease in the lymphadenopathy. After four additional cycles of ABVD, repeat staging revealed new gallium-avid disease in the right paratracheal region, with stable disease upon CT scan. Repeat bone marrow biopsy was negative. The patient was considered to have refractory disease and underwent salvage therapy with rituximab, ifosfamide, carboplatin, and etoposide. After two cycles, he had a negative gallium

show abstract

A New Combination Chemotherapy for Resistant Hodgkin Disease

Vinciguerra¹

1977

JAMA

View full text Add to dashboard Cite

Single-Agent Therapy for Hodgkin's Disease

Cited by 32 publications

References 59 publications

Hodgkin's Disease Presenting with Fulminant Liver Disease

Hodgkin's Disease Presenting with Fulminant Liver Disease

Salvage Therapy in Hodgkin's Lymphoma

A New Combination Chemotherapy for Resistant Hodgkin Disease

Contact Info

Product

Resources

About